Adrien Lupieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adrien Lupieri has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Elena Aikawa
Center for Interdisciplinary Cardiovascular Sciences, Brigham and Women's Hospital, Harvard Medical School , 3 Blackfan Street, 17th Floor, Boston, MA 02115
9 shared publications - Muriel Laffargue
Department of Vascular Biology of the Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse 3, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1048, Toulouse, France
7 shared publications - Masanori Aikawa
The Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, United States
6 shared publications Nicole Malet
6 shared publications- Stéphanie Gayral
Department of Vascular Biology of the Institute of Metabolic and Cardiovascular Diseases (I2MC), Université de Toulouse 3, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1048, Toulouse, France
6 shared publications - Natalia F. Smirnova
1 Institute of Metabolic and Cardiovascular Diseases (I2MC), Institut National de la Santé et de la Recherche Médicale (INSERM) U1297, University of Toulouse 3, Toulouse, France
5 shared publications
Latest Publications
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Fonctions catalytique et non-catalytique de la PI3Ky dans la réponse artérielle aux stress
La physiopathologie artérielle comprend différentes pathologies telles que l'hypertension, l'athérosclérose, l'hyperplasie intimale qui sont caractérisées par un remodelage artériel en réponse à différents stress environnementaux. Mon travail de thèse s'est intéressé à décrire les mécanismes cellulaires et moléculaires mis en jeu en réponse à un stress artériel dans des modèles murins et de proposer de nouvelles approches thérapeutiques dans la prévention des dommages artériels. Ainsi, nous nous sommes intéressés au rôle d'une isoforme particulière de la famille des phosphoinositide 3-kinase, la PI3Ky. Cette protéine est largement exprimée dans le compartiment hématopoïétique, où son activité catalytique intervient dans l'inflammation de la paroi artérielle, mais elle est également présente à de plus faible niveau dans les CML et les CE. Associée à son rôle catalytique largement impliqué dans la migration et la libération de facteurs inflammatoires, la PI3Ky a été décrite comme ayant des fonctions non-catalytiques, dite " d'ancrage ", activant des phosphodiestérases (PDE). Ainsi, en utilisant deux modèles murins génétiquement modifiés pour la PI3Ky, l'un délété pour la PI3Ky (PI3KyKO pour knockout) et l'autre exprimant une forme inactive de la PI3Ky (PI3KyKD pour kinase dead) nous avons pu évaluer le rôle des 2 fonctions dans des modèles murins de lésions artérielle. Dans un premier temps, nous nous sommes intéressés au rôle non-catalytique de la PI3Ky dans les CML. A partir d'un modèle murin de remodelage artériel induit par un stress hypertenseur nous avons observé que l'hyperplasie médiale des CML est dépendante de la PI3Ky, mais indépendante de son activité catalytique. In vitro à partir de cultures primaires de CML de souris nous avons démontré que la PI3Ky régule l'activité des PDE indépendamment de son activité, limitant les taux intracellulaires d'AMPc qui est un puissant frein de la prolifération des CML. Ces modèles nous ont aussi permis de tester une stratégie thérapeutique originale utilisant un peptide perméant inhibant l'interaction PI3Ky/PDE. Ce peptide est capable de prévenir à la fois la prolifération des CML in vitro mais aussi l'hyperplasie médiale in vivo. Dans un deuxième temps, nous avons étudié comment l'activité PI3Ky inflammatoire, inhibe la cicatrisation endothéliale suite à une lésion endovasculaire. A l'aide de différents modèles in vivo et ex vivo de réendothélialisation chez la souris, nous avons pu observer que suite à une lésion vasculaire l'activité de PI3Ky des lymphocytes T induit la sécrétion d'IFNy, entrainant une production locale de CXCL10 par les CML. Cette chimiokine va directement inhiber la cicatrisation endothéliale, indépendamment du compartiment immun. Ces travaux ont permis d'une part de démontrer que l'inhibition de la PI3Ky représentait une stratégie thérapeutique envisageable dans les complications de l'angioplastie mais ont également permis de montrer les mécanismes d'interactions cellulaires complexes mis en jeu lors d'une agression artérielle. Ils ont notamment permis de démontrer un rôle central de la CML agissant comme un relai entre l'inflammation adventitielle et l'endothélium. L'ensemble de ces données a pu mettre en avant une double fonction de la PI3Ky dans les processus de réponse à un stress inflammatoire ou hémodynamique. D'une part, son rôle pro-inflammatoire contrôlé par son activité catalytique, responsable d'une inhibition de la cicatrisation endothéliale via l'activation des CML. D'autre part, son rôle non-catalytique dans les CML, modulant leur prolifération via la signalisation de l'AMPc. Ces travaux permettent d'envisager de nouvelles stratégies thérapeutiques visant d'une part à inhiber son activité en utilisant des inhibiteurs hautement spécifiques pour cette isoforme et d'autre part des peptides capables de bloquer le rôle non catalytique de la PI3Ky.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Fonctions catalytique et non-catalytique de la PI3Ky dans la réponse artérielle aux stress
La physiopathologie artérielle comprend différentes pathologies telles que l'hypertension, l'athérosclérose, l'hyperplasie intimale qui sont caractérisées par un remodelage artériel en réponse à différents stress environnementaux. Mon travail de thèse s'est intéressé à décrire les mécanismes cellulaires et moléculaires mis en jeu en réponse à un stress artériel dans des modèles murins et de proposer de nouvelles approches thérapeutiques dans la prévention des dommages artériels. Ainsi, nous nous sommes intéressés au rôle d'une isoforme particulière de la famille des phosphoinositide 3-kinase, la PI3Ky. Cette protéine est largement exprimée dans le compartiment hématopoïétique, où son activité catalytique intervient dans l'inflammation de la paroi artérielle, mais elle est également présente à de plus faible niveau dans les CML et les CE. Associée à son rôle catalytique largement impliqué dans la migration et la libération de facteurs inflammatoires, la PI3Ky a été décrite comme ayant des fonctions non-catalytiques, dite " d'ancrage ", activant des phosphodiestérases (PDE). Ainsi, en utilisant deux modèles murins génétiquement modifiés pour la PI3Ky, l'un délété pour la PI3Ky (PI3KyKO pour knockout) et l'autre exprimant une forme inactive de la PI3Ky (PI3KyKD pour kinase dead) nous avons pu évaluer le rôle des 2 fonctions dans des modèles murins de lésions artérielle. Dans un premier temps, nous nous sommes intéressés au rôle non-catalytique de la PI3Ky dans les CML. A partir d'un modèle murin de remodelage artériel induit par un stress hypertenseur nous avons observé que l'hyperplasie médiale des CML est dépendante de la PI3Ky, mais indépendante de son activité catalytique. In vitro à partir de cultures primaires de CML de souris nous avons démontré que la PI3Ky régule l'activité des PDE indépendamment de son activité, limitant les taux intracellulaires d'AMPc qui est un puissant frein de la prolifération des CML. Ces modèles nous ont aussi permis de tester une stratégie thérapeutique originale utilisant un peptide perméant inhibant l'interaction PI3Ky/PDE. Ce peptide est capable de prévenir à la fois la prolifération des CML in vitro mais aussi l'hyperplasie médiale in vivo. Dans un deuxième temps, nous avons étudié comment l'activité PI3Ky inflammatoire, inhibe la cicatrisation endothéliale suite à une lésion endovasculaire. A l'aide de différents modèles in vivo et ex vivo de réendothélialisation chez la souris, nous avons pu observer que suite à une lésion vasculaire l'activité de PI3Ky des lymphocytes T induit la sécrétion d'IFNy, entrainant une production locale de CXCL10 par les CML. Cette chimiokine va directement inhiber la cicatrisation endothéliale, indépendamment du compartiment immun. Ces travaux ont permis d'une part de démontrer que l'inhibition de la PI3Ky représentait une stratégie thérapeutique envisageable dans les complications de l'angioplastie mais ont également permis de montrer les mécanismes d'interactions cellulaires complexes mis en jeu lors d'une agression artérielle. Ils ont notamment permis de démontrer un rôle central de la CML agissant comme un relai entre l'inflammation adventitielle et l'endothélium. L'ensemble de ces données a pu mettre en avant une double fonction de la PI3Ky dans les processus de réponse à un stress inflammatoire ou hémodynamique. D'une part, son rôle pro-inflammatoire contrôlé par son activité catalytique, responsable d'une inhibition de la cicatrisation endothéliale via l'activation des CML. D'autre part, son rôle non-catalytique dans les CML, modulant leur prolifération via la signalisation de l'AMPc. Ces travaux permettent d'envisager de nouvelles stratégies thérapeutiques visant d'une part à inhiber son activité en utilisant des inhibiteurs hautement spécifiques pour cette isoforme et d'autre part des peptides capables de bloquer le rôle non catalytique de la PI3Ky.
- Open Access
- 1 April 2026
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 3 (2) , 176-178
In Memoriam—Robert A. Levine (1953-2026)
- 1 April 2026
- Published by SAGE Publications in Journal of the Heart Valve Society
- Vol. 3 (2) , 176-178
Open AccessIn Memoriam—Robert A. Levine (1953-2026)
- Open Access
Selective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease
BACKGROUND Calcific aortic valve disease (CAVD) compromises valve compliance and cardiac hemodynamics leading to aortic stenosis (AS) and cardiovascular dysfunction. With treatment for severe AS limited to valve replacement and no effective pharmacotherapies, new interventions are urgently needed for patients. This study evaluated pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARa) activator as a novel therapeutic for CAVD and AS. METHODS AND RESULTS In an aortic valve wire injury (AVWI) model of AS in Ldlr-/- mice, pemafibrate administration (0.2 mg/kg/day) for 15 weeks improved aortic valve function and reduced valvular calcification by 39% (p<0.001), accompanied by reduced leaflet inflammation and CD68+; macrophage infiltration. These effects were independent of changes in plasma triglyceride levels. In vitro, pemafibrate suppressed inflammation-mediated calcification of primary human valvular interstitial cells (VICs) by modulating macrophage-derived secreted factors, identifying macrophage-VIC crosstalk as a key disease mechanism. Direct treatment of macrophages with pemafibrate, or exposure to serum from pemafibrate-treated participants in the PROMINENT randomized controlled trial, shifted macrophages toward a less inflammatory and less chemotactic phenotype. Proteomic analyses of patient serum substantiated these findings by reflecting a systemic reduction in inflammatory parameters and monocyte activation. Network integration of the in vitro derived pemafibrate-responsive proteome with human calcified AV tissue proteomes identified aberrant protein translation (GNB2L1, GSPT1) and disrupted bioenergetics (MYDGF, PDIA4) as potential clinically relevant pemafibrate-responsive pathways and effector proteins relevant to AS progression. CONCLUSIONS Pemafibrate slows experimental AS progression and valve calcification through modulation of macrophage-VIC crosstalk, independent of lipid lowering. These findings support further evaluation of pemafibrate as a potential pharmacological approach for CAVD and support further testing in randomized clinical trials.
Open AccessSelective PPAR-α activation with pemafibrate attenuates macrophage-mediated progression of calcific aortic valve disease
BACKGROUND Calcific aortic valve disease (CAVD) compromises valve compliance and cardiac hemodynamics leading to aortic stenosis (AS) and cardiovascular dysfunction. With treatment for severe AS limited to valve replacement and no effective pharmacotherapies, new interventions are urgently needed for patients. This study evaluated pemafibrate, a selective peroxisome proliferator-activated receptor alpha (PPARa) activator as a novel therapeutic for CAVD and AS. METHODS AND RESULTS In an aortic valve wire injury (AVWI) model of AS in Ldlr-/- mice, pemafibrate administration (0.2 mg/kg/day) for 15 weeks improved aortic valve function and reduced valvular calcification by 39% (p<0.001), accompanied by reduced leaflet inflammation and CD68+; macrophage infiltration. These effects were independent of changes in plasma triglyceride levels. In vitro, pemafibrate suppressed inflammation-mediated calcification of primary human valvular interstitial cells (VICs) by modulating macrophage-derived secreted factors, identifying macrophage-VIC crosstalk as a key disease mechanism. Direct treatment of macrophages with pemafibrate, or exposure to serum from pemafibrate-treated participants in the PROMINENT randomized controlled trial, shifted macrophages toward a less inflammatory and less chemotactic phenotype. Proteomic analyses of patient serum substantiated these findings by reflecting a systemic reduction in inflammatory parameters and monocyte activation. Network integration of the in vitro derived pemafibrate-responsive proteome with human calcified AV tissue proteomes identified aberrant protein translation (GNB2L1, GSPT1) and disrupted bioenergetics (MYDGF, PDIA4) as potential clinically relevant pemafibrate-responsive pathways and effector proteins relevant to AS progression. CONCLUSIONS Pemafibrate slows experimental AS progression and valve calcification through modulation of macrophage-VIC crosstalk, independent of lipid lowering. These findings support further evaluation of pemafibrate as a potential pharmacological approach for CAVD and support further testing in randomized clinical trials.
- Open Access
- 9 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (21)
A systems approach to target discovery identifies the role of lncRNA-SPANXA2-OT1 in macrophage chemotaxis
Coronary artery disease (CAD) is the leading cause of mortality worldwide, with macrophages playing a central role in shaping the inflammatory environment through cytokines, chemokines, and other mediators. Long noncoding RNAs (lncRNAs) are emerging as key regulators of cellular processes owing to their interactions with DNA, RNA, microRNAs, and proteins, which positions them to be promising therapeutic targets. Through integrative transcriptomic analysis, we identified SPANXA2-OT1 as a primate-specific lncRNA with a potential role in macrophage-mediated inflammation in CAD. Functional studies in primary human macrophages demonstrated that SPANXA2-OT1 was induced by inflammatory stimulation, localized to the cytoplasm, and exerted regulatory effects on chemokine expression and macrophage chemotaxis. Mechanistically, SPANXA2-OT1 acted as a molecular sponge for microRNA-338, thereby influencing the expression of IL-8 , a critical mediator of monocyte recruitment and inflammatory signaling. Collectively, these findings establish SPANXA2-OT1 as a human-specific regulator of inflammatory pathways in CAD and highlight its translational potential as both a biomarker and therapeutic target.
- 9 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (21)
Open AccessA systems approach to target discovery identifies the role of lncRNA-SPANXA2-OT1 in macrophage chemotaxis
Coronary artery disease (CAD) is the leading cause of mortality worldwide, with macrophages playing a central role in shaping the inflammatory environment through cytokines, chemokines, and other mediators. Long noncoding RNAs (lncRNAs) are emerging as key regulators of cellular processes owing to their interactions with DNA, RNA, microRNAs, and proteins, which positions them to be promising therapeutic targets. Through integrative transcriptomic analysis, we identified SPANXA2-OT1 as a primate-specific lncRNA with a potential role in macrophage-mediated inflammation in CAD. Functional studies in primary human macrophages demonstrated that SPANXA2-OT1 was induced by inflammatory stimulation, localized to the cytoplasm, and exerted regulatory effects on chemokine expression and macrophage chemotaxis. Mechanistically, SPANXA2-OT1 acted as a molecular sponge for microRNA-338, thereby influencing the expression of IL-8 , a critical mediator of monocyte recruitment and inflammatory signaling. Collectively, these findings establish SPANXA2-OT1 as a human-specific regulator of inflammatory pathways in CAD and highlight its translational potential as both a biomarker and therapeutic target.
- 1 August 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (8) , 1398-1415
Antisense Oligonucleotide Targeting Sortilin Reduces Vascular Calcification in Mice in a Sex-Dependent Manner
BACKGROUND: Atherosclerotic calcification is a complex pathological process associated with an increased risk of cardiovascular events. Despite extensive research, this disorder has no effective therapeutic strategies. In this study, we evaluated the therapeutic potential of silencing Sort (sortilin) expression in vivo using antisense oligonucleotide (ASO-Sort1) to reduce the development of atherosclerosis and associated calcification. METHODS: Male and female Ldlr −/− (low-density lipoprotein receptor knock-out) mice were fed a high-fat diet and treated with ASO-Sort1 for 15 weeks. After ASO-Sort1 treatment, we evaluated atherosclerotic lesion formation and calcification through molecular imaging and histological techniques. The levels of plasma lipid and inflammatory molecules were determined. Unbiased liquid chromatography-mass spectrometry–based proteomics of aortic arches was conducted to investigate the sex-specific regulation in ASO-Sort1–treated mice. To validate our in vivo findings, we conducted in vitro experiments to examine whether β-estradiol treatment of mouse smooth muscle cells promotes calcification independently of Sort. RESULTS: ASO targeted primarily arterial smooth muscle cells, leading to a comparable reduction of aortic Sort1 expression by ≈57% in males and 52% in females. Although ASO-Sort1 did not affect the size of atherosclerotic lesions, it significantly reduced necrotic core development by 60% in male and 40% in female mice. In addition, it prevented aortic calcification by >50% only in male mice. Furthermore, proteome analysis revealed that while this treatment reduced vesicular trafficking, immune system, and extracellular matrix organization pathways in both male and female mice, it reduced autophagy-related processes specifically in males. In vitro results indicated that β-estradiol promotes calcification in smooth muscle cells treated with ASO-Sort1 by altering autophagy. CONCLUSIONS: Targeting Sort using antisense technology is effective in preventing vascular calcification in male mice. This unexpected outcome highlighted a novel sex-dependent discrepancy of the calcification pathway implicating the alteration of autophagy by β-estradiol and Sort.
- 1 August 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (8) , 1398-1415
Antisense Oligonucleotide Targeting Sortilin Reduces Vascular Calcification in Mice in a Sex-Dependent Manner
BACKGROUND: Atherosclerotic calcification is a complex pathological process associated with an increased risk of cardiovascular events. Despite extensive research, this disorder has no effective therapeutic strategies. In this study, we evaluated the therapeutic potential of silencing Sort (sortilin) expression in vivo using antisense oligonucleotide (ASO-Sort1) to reduce the development of atherosclerosis and associated calcification. METHODS: Male and female Ldlr −/− (low-density lipoprotein receptor knock-out) mice were fed a high-fat diet and treated with ASO-Sort1 for 15 weeks. After ASO-Sort1 treatment, we evaluated atherosclerotic lesion formation and calcification through molecular imaging and histological techniques. The levels of plasma lipid and inflammatory molecules were determined. Unbiased liquid chromatography-mass spectrometry–based proteomics of aortic arches was conducted to investigate the sex-specific regulation in ASO-Sort1–treated mice. To validate our in vivo findings, we conducted in vitro experiments to examine whether β-estradiol treatment of mouse smooth muscle cells promotes calcification independently of Sort. RESULTS: ASO targeted primarily arterial smooth muscle cells, leading to a comparable reduction of aortic Sort1 expression by ≈57% in males and 52% in females. Although ASO-Sort1 did not affect the size of atherosclerotic lesions, it significantly reduced necrotic core development by 60% in male and 40% in female mice. In addition, it prevented aortic calcification by >50% only in male mice. Furthermore, proteome analysis revealed that while this treatment reduced vesicular trafficking, immune system, and extracellular matrix organization pathways in both male and female mice, it reduced autophagy-related processes specifically in males. In vitro results indicated that β-estradiol promotes calcification in smooth muscle cells treated with ASO-Sort1 by altering autophagy. CONCLUSIONS: Targeting Sort using antisense technology is effective in preventing vascular calcification in male mice. This unexpected outcome highlighted a novel sex-dependent discrepancy of the calcification pathway implicating the alteration of autophagy by β-estradiol and Sort.
- Open Access
- 5 July 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (4)
Ticagrelor promotes arterial healing and shows superiority to clopidogrel in preventing neoatherosclerosis
- 5 July 2025
- Published by Elsevier in Blood Vessels, Thrombosis & Hemostasis
- Vol. 2 (4)
Open AccessTicagrelor promotes arterial healing and shows superiority to clopidogrel in preventing neoatherosclerosis
- 1 July 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (7) , 1041-1043
Metabolic Rewiring in Calcific Aortic Valve Disease: It Goes Beyond Immunometabolism
- 1 July 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (7) , 1041-1043
Metabolic Rewiring in Calcific Aortic Valve Disease: It Goes Beyond Immunometabolism
- 20 May 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (6) , 844-846
Decoding calcific aortic valve disease: is liver X receptor the key to lipid metabolism?
- 20 May 2025
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 121 (6) , 844-846
Decoding calcific aortic valve disease: is liver X receptor the key to lipid metabolism?
- Open Access
- 13 March 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1537104
Rheumatic heart valve disease: navigating the challenges of an overlooked autoimmune disorder
Despite being a leading cause of morbidity and mortality among young people, affecting predominantly women, rheumatic heart disease (RHD) remains neglected and understudied. This autoimmune condition arises from a complex continuum that begins with repeated Group A Streptococcal (GAS) pharyngitis, leading to acute rheumatic fever (ARF) that eventually results in damage to the heart, mainly affecting the mitral valve. While RHD has been nearly eradicated in high-income countries, it continues to be a significant and active health issue in low- and middle-income countries. The resolution of this disease faces several challenges, including the difficulty of diagnosis and the lack of access to preventive measures in resource-poor communities. Addressing these issues will require a global health collaboration involving healthcare professionals, policymakers, and advocacy groups. However, over the past two decades, there has been a revival of scientific interest, fostering optimism for the future. Recent research has significantly advanced our understanding of RHD, shedding light on the immune-to-autoimmune transition, neoangiogenesis, and lymphangiogenesis processes. Additionally, perspectives of discoveries in biomarkers and the development of genetic, transcriptomic, and provide a solid foundation for further advancements in the field.
- 13 March 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1537104
Open AccessRheumatic heart valve disease: navigating the challenges of an overlooked autoimmune disorder
Despite being a leading cause of morbidity and mortality among young people, affecting predominantly women, rheumatic heart disease (RHD) remains neglected and understudied. This autoimmune condition arises from a complex continuum that begins with repeated Group A Streptococcal (GAS) pharyngitis, leading to acute rheumatic fever (ARF) that eventually results in damage to the heart, mainly affecting the mitral valve. While RHD has been nearly eradicated in high-income countries, it continues to be a significant and active health issue in low- and middle-income countries. The resolution of this disease faces several challenges, including the difficulty of diagnosis and the lack of access to preventive measures in resource-poor communities. Addressing these issues will require a global health collaboration involving healthcare professionals, policymakers, and advocacy groups. However, over the past two decades, there has been a revival of scientific interest, fostering optimism for the future. Recent research has significantly advanced our understanding of RHD, shedding light on the immune-to-autoimmune transition, neoangiogenesis, and lymphangiogenesis processes. Additionally, perspectives of discoveries in biomarkers and the development of genetic, transcriptomic, and provide a solid foundation for further advancements in the field.
- 1 April 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (4) , 822-825
Lymphangiogenesis in Rheumatic Heart Valve Disease: A New Factor in the Pathogenic Conundrum
- 1 April 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (4) , 822-825
Lymphangiogenesis in Rheumatic Heart Valve Disease: A New Factor in the Pathogenic Conundrum